Measurement of Pharmaceutical and Diagnostic Inhalation Aerosols

Aerosol Measurement: Principles, Techniques, and Applications: Third Edition

Volumn , Issue , 2011, Pages 805-820

  Hickey, Anthony J ^a   Swift, David ^b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Effective aerosol measurement and biological assay techniques in health care; Pharmaceutical and diagnostic inhalation aerosol measurement in health related settings; Pharmaceutical, and diagnostic inhalation aerosol characterization therapeutic aerosols

Indexed keywords

EID: 84887348885     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118001684.ch39     Document Type: Chapter

References (66)

1. Adi, S., H. Adi, H. K. Chan, P. M. Young, D. Traini, R. Yang, and A. Yu. 2008. Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation. Langmuir 24(19):11307-11312.
2. Adjei, A., and P. Gupta. 1994. Pulmonary delivery of therapeutic peptides and proteins. J. Controlled Release 29(3):361-373.
3. Agnew I. E. 1984. Aerosol contributions to the investigations of lung structure and ventilation function. In Aerosols and the Lung, eds. S. W. Clarke and D. Pavia. London: Butterworths.
4. Allen, J. O., D. P. Fergenson, E. E. Gard, L. S. Hughes, B. D. Morrical, M. J. Kleeman, D. S. Gross, M. E. Galli, K. A. Prather, and G. R. Crass. 2000. Particle detection efficiencies of aerosol time of flight mass spectrometers under ambient sampling conditions. Environ. Sci. Technol. 34:211-217.
5. Asgharian, B.,W. Hofmann, and R. Bergmann. 2001. Particle deposition in a multiple-path model of the human lung. Aerosol Sci. Technol. 34:332-339.
6. Atkins, P. J., and T. M. Crowder. 2004. The design and development of inhalation drug delivery systems. In Pharmaceutical Inhalation Aerosol Technology, 2nd ed., ed. A. J. Hickey. New York: Marcel Dekker, pp. 279-309.
7. Babich, S., and R. P. Burakoff. 1997. Occupational hazards of dentistry. A review of literature from 1990. N. Y. State Dent. J. 63:26-31.
8. Behr, J., G. Zimmermann, R. Baumgartner, H. Leuchte, C. Neurohr, P. Brand, C. Herpich, K. Sommerer, J. Seitz, G. Menges, S. Tillmanns, and M. Keller. 2009. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J. Aerosol Med. Pulm. Drug Del. 22(2):121-129.
9. Bell, I. H., P. S. Hartley, and J. S. G. Cox. 1971. Dry power aerosols 1: A new powder inhalation device. J. Pharm. Sci. 60:1159-1164.
10. Berry, J., S. Heimbecher, J. L. Hart, and J. Sequeira. 2003. Influence of the metering chamber volume and actuator design on the aerodynamic particle size of a metered dose inhaler. Drug Dev. Indust. Pharm. 29:865-876.
11. Block, S. S. 2001. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia: Lippincott Williams and Wilkins, pp. 3-18.
12. Byron, P. R. 1986. Prediction of drug residence times in regions of the human respiratory tract following aerosols inhalation. J. Pharm. Sci. 75:433-436.
13. Byron, P. R., and J. S. Patton. 1994. Drug delivery via the respiratory tract. J. Aerosol Med. 7:49-75.
14. Chan, H. K. 2006. Dry powder aerosol delivery systems: Current and future research directions. J. Aerosol Med. 19(1):21-27.
15. Clark, B., and D. A. Smith. 1981. An Introduction to Pharmacokinetics. Oxford: Blackwell, p. 1.
16. Dalby R N., S. L. Tiano, and A. J. Hickey. 2007. Medical devices for delivery of therapeutic aerosols to the lungs. In Inhalation Aerosols, Physical and Biological Basis for Therapy, 2nd ed., ed. A. J. Hickey. New York: Informa Healthcare, pp. 417-444.
17. de Boer A. H., D. Gjaltema, P. Hagedoorn, and H.W. Frijlink. 2002. Characterization of inhalation aerosols: A critical evaluation of cascade impactor analysis and laser diffraction technique. Int. J. Pharm. 249:219-231.
18. Deshpande, D. S., J. D. Blanchard, J. Schuster, D. Fairbanks, C. Hobbs, R. Beihn, C. Densmore, S. Farr, and I. Gonda. 2005. Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J. Aerosol Med. 18(1):34-44.
19. Dolovich, M. A. 2000. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 45(6):597-608.
20. Dunbar, C. A., A. J. Hickey, and P. Holzner. 1998. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA 16:7-45.
21. Edsbacker, S., and M. Jendbro. 1998. Modes to achieve topical selectivity of inhaled glucocorticosteroids-c: Focus on budesonide. In Respiratory Drug Delivery VI, eds. R. N. Dalby, P. R. Byron, and S. J. Farr. Buffalo Grove, IL: Interpharm Press, pp. 71-82.
22. Ferrari, F., Z.-H. Liu, Q. Lu, M.-H. Becquemin, K. Louchahi, G. Aymard, C.-H. Marquette, and J.-J. Rouby. 2008. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: Ultrasonic versus vibrating plate nebulizers. Intensive Care Medicine 34(9):1718-1723.
23. Finlay, W. H. 2001. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction, New York: Academic.
24. Garcia-Contreras, L., and A. J. Hickey. 2002. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv. Drug Deliv. Rev. 54(11):1491-1504.
25. Gonda, I. 1988. Drugs administered directly into the respiratory tract: Modeling of the duration of effective drug levels. J Pharm. Sci. 77:340-346.
26. Gonda, I. 2004. Targeting by deposition. In Pharmaceutical Inhalation Aerosol Technology, 2nd ed., ed. A. J. Hickey. New York: Marcel Dekker, pp. 65-88.
27. Goldman, L. 2006. A review: Applications of the laser beam in cancer biology. Int. J. Cancer 1:309-318.
28. Gorman,W. G., and E. A. Carroll. 1993. Aerosol particle-size determination using laser holography. Pharm. Tech. 17(2):34-37.
29. Hannemann, L. A. 1999. What is new in asthma?: New dry powder inhalers. J. Pediatr. Health Care 13(4):159-165.
30. Harrel, S. K., and J. Molinari. 2004. Aerosols and splatter in dentistry: A brief review of the literature and infection control implications. J. Am. Dent. Assoc. 135:429-437.
31. Heyder, J. 1988. Assessment of airway geometry with inert aerosols. J. Aerosol Med. 1:167-171.
32. Hickey, A. J. 2002. Delivery of drugs by the pulmonary route. In Modern Pharmaceutics, 4th ed., eds. G. S. Banker and C. T. Rhodes. New York: Marcel Dekker, pp. 479-499.
33. Hickey, A. J. 2007. Methods of aerosol particle size analysis. In Pharmaceutical Inhalation Aerosol Technology, 2nd ed., ed. A. J. Hickey. New York: Marcel Dekker, pp. 345-384.
34. Hinds, W. C. 1999. Aerosol Technology: Properties, Behavior, and Measurement of Airhorne Particles. New York: John Wiley & Sons.
35. Hochhaus, G., S. Suarez, R. I. Gonzalez-Rothi, and H. Schreier. 1998. Pulmonary targeting of inhaled glucocorticoids: How is it influenced by formulation. In Respiratory Drug Delivery VI, eds. R. N. Dalby, P. R. Byron, and S. J. Farr. Buffalo Grove, IL: Interpharm Press, pp. 45-52.
36. Ijsebaert, J. C., K. B. Geerse, J. C. M. Marijnissen, J.-W. J. Lammers, and P. Zanen. 2001. Electro-hydrodynamic atomization of drug solutions for inhalation purposes. J. Appl. Physiol. 91:2735-2741.
37. Jaegfeldt, A., J. Anderson, E. Trofast, and K.Welterlin. 1987. A new concept in inhalation therapy. In Proceedings of an International Workshop on a New Inhaler, eds. S. Newman, F. Moren, and Crompton. London: Medicom.
38. Kjellman, N., and B.Wirenstrand. 1981. Letter to the editor. Allergy 36:437-438.
39. Krilov, L. R. 2002. Safety issues related to the administration of ribavirin. Pediatr. Infect. Dis. J. 21(5):479-481.
40. Le Brun, P. P., A. H. de Boer, H. G. Heijerman, and H. W. Frijlink. 2000. A review of the technical aspects of drug nebulization. Pharm World Sci. 22:75-81.
41. Macalino, G. E., K. W. Springer, Z. S. Rahman, D. Vlahov, and T. S. Jones. 1998. Community-based programs for safe disposal of used needles and syringes. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(Suppl 1):S111-S119.
42. Mercer, T. T. 1981. Production of therapeutic aerosols: Principles and techniques. Chest 80(Suppl 1):813-818.
43. Merritt,W. H., andW. R. Myers. 1991. Real time aerosol monitoring during laser surgery. Paper presented at the 1991 American Industrial Hygienists Conference, Salt Lake City, UT, May 18-24.
44. Mitchell, J. P., and M.W. Nagel. 2004. Particle size analysis of aerosols from medicinal inhalers. KONA 22:32-64.
45. Mitchell, J. P., M. W. Nagel, S. Nichols, and O. Nerbrink. 2006. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J. Aerosol Med. 19:409-433.
46. NCRP. 1997. Deposition, Retention, and Dosimetry of Inhaled Radioactive Substances, NCRP Report No. 125. National Council on Radiation Protection and Measurements, Bethesda, MD.
47. Newman, S. 1984. Therapeutic aerosols. In Aerosols and the Lung, eds. S. W. Clarke and D. Pavia. London: Butterworths.
48. Newman, S. P. 2003a. Deposition and effects of inhaled corticosteroids. Clin. Pharmacokinet. 42(6):529-544.
49. Newman, S. P. 2003b. Drug delivery to the lungs from dry powder inhalers. Curr. Opin. Pulm. Med. 9(Suppl 1):S17-S20.
50. Niven, R W., and A. J. Hickey. 2007. Atomization and nebulizers. In Inhalation Aerosols, Physical and Biological Basis for Therapy, 2nd ed., ed. A. J. Hickey. New York: Marcel Dekker, pp. 253-283.
51. Obaji, J., L. R. Lee-Pack, C. Gutierrez, and C. K. Chan. 2003. The pulmonary effects of long-term exposure to aerosol pentamidine: A 5-year surveillance study in HIV-infected patients. Chest 123(6):1983-1987.
52. Phipps, P., I. Gonda, D. Bailey, P. Borham, G. Bautovich, and S. Anderson. 1989. Comparison of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am. Rev. Respir Dis. 139:1516-1523.
53. Pritchard, J. N. 2001. The influence of lung deposition on clinical response. J. Aerosol Med. 14(Suppl 1):S19-S26.
54. Purewal, T. S., and D. J. W. Grant. 1998. Metered Dose Inhaler Technology. Buffalo Grove, IL: Interpharm Press.
55. Ranucci, J., and E-C. Chen. 1993. Phase Doppler anemometry: A technique for determining aerosol plume-particle size and velocity. Pharm. Tech. 17:62-74.
56. Riley, R. L. 1972. The ecology of indoor atmospheres: Airborne infections in hospitals. 1. Chronic Dis. 25:421-430.
57. Riley, R. L. 1974. Airborne infection. Am. J. Med. 57:466-475.
58. Sermet-Gaudelus, I., Y. Le Cocguic, A. Ferroni, M. Clairicia, J. Barthe, J. P. Delaunay, V. Brousse, and G. Lenoir. 2002. Nebulized antibiotics in cystic fibrosis. Paediatr. Drugs 4(7):455-467.
59. Suarez, S., and A. J. Hickey. 2001. Pharmacokinetic and pharmacodynamic aspects of inhaled therapeutic agents. In Medical Applications of Computer Modelling: The Respiratory System, ed. T Martonen. Southampton, UK: WIT Press, pp. 225-304.
60. Swift, D. L., B. Asgharian, and J. S. Kimbell. 2007. Use of mathematical aerosol deposition models in predicting the distribution of inhaled therapeutic aerosols. In Inhalation Aerosols, Physical and Biological Basis for Therapy, 2nd ed., ed. A. J. Hickey. New York: Informa Healthcare, pp. 55-82.
61. Taplin, G. V., and S. K. Chopra. 1978. Inhalation lung imaging with radioactive aerosols and gases. Prog. Nuclear Med. 5:119-120.
62. Xu, R. 2000. Particle Characterization: Light Scattering Methods. New York: Kluwer Academic.
63. Wagner, H. N. 1976. The use of radioisotope techniques for the evaluation of patients with pulmonary disease. Am. Rev. Respir. Dis. 113:203-218.
64. Walker, S. R., M. Evans, M. E. Richards, and J. W. Paterson. 1972. The fate of (14C) disodium cromoglycate in man. J. Pharm. Pharmacol. 24:525-531.
65. Wells, W. E. 1955. Airborne Contagion and Air Hygiene. Cambridge: Harvard University Press.
66. Zimmerman, P. E., R. K. Larsen, E. W. Barkley, and J. F. Gallelli. 1981. Recommendations for the safe handling of injectable antineoplastic drug products. Am. J. Hosp. Pharm. 38:1693-1695.